alexa Pharmaceutical Equivalence and Bioequivalence of Radiopharmaceuticals:Thinking the Possibility of Generic Radiopharmaceuticals and Preparing for New Technology as Nanotechnology Drugs

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

World Clinical Cancer Research and Diagnosis

Tokyo, Japan

Global Summit on Oncology and Cancer Therapy

New York, USA

Advancement in Drug Discovery

New York, USA
Pharmaceutical Equivalence and Bioequivalence of Radiopharmaceuticals:Thinking the Possibility of Generic Radiopharmaceuticals and Preparing for New Technology as Nanotechnology Drugs

The use of radiopharmaceuticals has been growing exponentially throughout the world, achieving notable numbers. Recent data estimates that in 2015 the market of Nuclear Medicine and Radiopharmacy surpass the mark of 1.5 trillion dollars, with more than 100 million people making use of these drugs around the world. In this scenario, so overwhelming, is surprising that there has not begun studies of pharmaceutical equivalence and bioequivalence of such drugs, especially with animal model and for therapeutics uses.

Citation: Santos-Oliveira R (2014) Pharmaceutical Equivalence and Bioequivalence of Radiopharmaceuticals: Thinking the Possibility of Generic Radiopharmaceuticals and Preparing for New Technology as Nanotechnology Drugs. J Bioequiv Availab 6:023-023. doi: 10.4172/jbb.1000175

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
Top